NASDAQ$ATAI
AtaiBeckley Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Atai reported a net loss for Q4 2024, with declining cash reserves and increased R&D spending.
Atai Life Sciences reported a net loss of $38.99 million for Q4 2024. The company's cash and equivalents decreased to $17.5 million, while research and development expenses rose to $18.94 million. Despite these financial challenges, the company continues progressing with its clinical trials, with topline data from key studies expected in 2025 and 2026.
- Reported a net loss of $38.99 million for Q4 2024.
- Cash and cash equivalents dropped to $17.5 million from $45 million in the previous year.
- R&D expenses increased to $18.94 million from $14.16 million in Q4 2023.
- Initiated and progressed multiple clinical trials, with topline data expected in 2025-2026.
Headline financials
Revenue & EPS history
Atai · Revenue · Quarterly
-$5
Forward guidance
Atai expects continued investment in clinical trials, with anticipated topline data from key programs in 2025 and 2026. The company aims to sustain its financial position through strategic funding initiatives.
Tailwinds
- Cash runway extended into 2027 due to a recent $59.2 million equity offering.
- Topline data from VLS-01 and EMP-01 expected in Q1 2026.
- Phase 2b trial completion for BPL-003 in mid-2025.
- Reduction in general and administrative expenses compared to the prior year.
- Continued strategic investment in Beckley Psytech and other pipeline programs.
Headwinds
- Net loss widened to $38.99 million in Q4 2024.
- Declining cash position, with only $17.5 million in cash and equivalents.
- Increased R&D expenses impacting short-term profitability.
- Dependency on successful trial outcomes for future revenue growth.
- Market uncertainties surrounding regulatory approval of key therapies.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
+0.7%
Avg return
Earnings day
+3.3%
Avg return
5 days after
+1.8%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+15.1%
Q4 2022
Best reaction
-17.7%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.5% | -0.5% | -6.0% | |
| Q4 2026 | -1.1% | +14.7% | +7.1% | |
| Q3 2025 | -2.0% | -10.6% | -3.2% | |
| Q2 2025 | -1.2% | -2.0% | +14.3% | |
| Q1 2025 | +1.4% | +30.5% | +49.6% | |
| Q4 2024 | -1.4% | -2.0% | -4.1% | |
| Q3 2024 | -6.2% | +14.4% | -6.8% | |
| Q2 2024 | -5.6% | -1.6% | -0.8% | |
| Q1 2024 | -2.6% | -9.4% | -28.3% | |
| Q4 2023 | +3.9% | +4.5% | +7.8% | |
| Q3 2023 | +4.3% | -3.5% | +11.3% | |
| Q2 2023 | -4.5% | -8.5% | -18.8% | |
| Q1 2023 | -5.0% | -3.0% | -12.5% | |
| Q4 2022 | +15.1% | +33.6% | +82.4% | |
| Q3 2022 | +1.1% | +5.9% | +17.6% | |
| Q2 2022 | +4.1% | -1.3% | -12.7% | |
| Q1 2022 | +13.2% | +9.9% | -9.1% | |
| Q4 2021 | -6.1% | -2.0% | -20.8% | |
| Q3 2021 | -17.7% | -21.9% | -54.3% | |
| Q1 2021 | +10.2% | +13.1% | +12.7% | |
| Q2 2021 | +13.0% | +9.0% | +11.5% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro